OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bal on the Safety Profile of BMS-986393 in R/R Multiple Myeloma

June 22nd 2023

Susan Bal, MD, discusses the toxicity profile of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, according to findings from a phase 1 trial.

Dr Bal on the Investigation of BMS-986393 in R/R Multiple Myeloma

June 21st 2023

Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.

Dr Komrokji on Ongoing Studies in Higher- and Lower-Risk MDS

June 21st 2023

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Dr Pant on the Investigation of Adagrasib in KRAS G12C–Mutated Solid Tumors

June 21st 2023

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Dr Ahmed on Real-World Findings With Brexu-Cel in MCL

June 21st 2023

Nausheen Ahmed, MD, discusses findings from a real-world subgroup analysis of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Dr Jänne on BL-B01D1 in NSCLC and Other Solid Tumors

June 21st 2023

Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.

Dr Costa on MRD-Modulated Post-ASCT Quadruplet Induction in Newly Diagnosed Multiple Myeloma

June 21st 2023

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

Dr Frank on the Initial Efficacy and Safety of CAR22 in Relapsed/Refractory LBCL

June 21st 2023

Matthew Frank, MD, PhD, discusses preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

Dr Nassar on Treatment Options After Chemoradiation in Unresectable, Stage III, EGFR-Mutated NSCLC

June 20th 2023

Amin Nassar, MD, discusses findings from a retrospective study of the use of EGFR TKI therapy, durvalumab, or observation following concurrent chemoradiation in patients with unresectable, stage III non–small cell lung cancer harboring EGFR mutations.

Dr Saba on Findings from the CONTINUUM Trial of Sintilimab in Nasopharyngeal Cancer

June 20th 2023

Nabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Dr Taieb on Findings from a Post-hoc Analysis of TAS-102 Plus Bevacizumab in Refractory mCRC

June 20th 2023

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

Dr Phillips on the Preliminary Efficacy of Acalabrutinib Plus BR in MCL

June 20th 2023

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion–Positive Cholangiocarcinoma

June 20th 2023

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

June 19th 2023

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

Dr Svoboda on the Implications of Nivolumab Plus AVD in Classical Hodgkin Lymphoma

June 19th 2023

Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.

Dr Vidula on the Evaluation of Talazoparib in BRCA1/2-Mutated Metastatic Breast Cancer

June 19th 2023

Neelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.

Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma

June 19th 2023

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Jacobs on the Preliminary Efficacy of TNB-486 in R/R Follicular Lymphoma

June 19th 2023

Ryan Jacobs, MD, hematologist and medical oncologist, Levine Cancer Institute, Atrium Health, discusses early responses with the novel CD19 and CD3 T-cell engager TNB-486 in relapsed/refractory follicular lymphoma according to a phase 1 study.

Dr Kim on the HARMONIC Trial of LP-300 in Advanced Lung Cancer

June 19th 2023

Edward S. Kim, MD, MBA, discusses the investigation of LP-300 plus chemotherapy in the phase 2 HARMONIC trial in patients with advanced lung adenocarcinoma.

Dr Shah on Long-Term Survival Data For Pirtobrutinib in BTK Inhibitor–Pretreated R/R MCL

June 16th 2023

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.